Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper-off: report on behalf of the Dutch Chronic Benzodiazepine Working Group

Br J Psychiatry. 2001 Apr:178:317-24. doi: 10.1192/bjp.178.4.317.

Abstract

Background: Many patients with depression take benzodiazepine drugs long term despite the absence of continuing therapeutic value.

Aims: To evaluate a treatment programme involving gradual discontinuation with or without simultaneous selective serotonin reuptake inhibitor (SSRI) prescribing and to determine the long-term outcome after benzodiazepine withdrawal.

Method: Patients went through three phases - change to an equivalent dose of diazepam; subsequent randomisation to either 20 mg of paroxetine or placebo; and gradual reduction of diazepam in depression-free patients - with a follow-up after 2 or 3 years.

Results: A total of 230 patients were recruited and 75% in the paroxetine group and 61% in the placebo group were successfully treated after 6 weeks (P:=0.067). After 2 or 3 years 13% of patients were still benzodiazepine free: 26% of those who had successfully tapered off benzodiazepine and 6% of the total group.

Conclusions: Transfer to diazepam followed by gradual withdrawal is an effective way of discontinuing chronic benzodiazepine use. The addition of SSRI treatment is of limited value.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Anxiety Agents / therapeutic use*
  • Antidepressive Agents, Second-Generation / therapeutic use*
  • Depressive Disorder / drug therapy*
  • Diazepam / therapeutic use
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Paroxetine / therapeutic use*
  • Sample Size
  • Selective Serotonin Reuptake Inhibitors / therapeutic use*
  • Substance Withdrawal Syndrome / prevention & control

Substances

  • Anti-Anxiety Agents
  • Antidepressive Agents, Second-Generation
  • Serotonin Uptake Inhibitors
  • Paroxetine
  • Diazepam